Accelerating the production of viral-vector based therapy requires both understanding of strategies to address viral vector manufacturing and how to select the most cost-effective solution for your therapeutic. Read more in this article.
Viral vectors have the potential to address unmet vaccines and there is currently a shortage in manufacturing capacity. Companies pursuing vaccine manufacturing as well as gene therapies must figure out a way to close the gap.
For many, this means facing a build versus buy capacity decision. Read the article to see why accelerating the production of viral-vector based therapy requires you to understand:
• The strategies available to address the viral vector manufacturing shortage
• How to select the most cost-effective solution for your next-generation therapeutic